Ask three different people at a research site what happens when a subject no-shows a protocol visit — the billing coordinator, the study coordinator, and the finance office — and it is common to get three different answers, because a single missed visit actually triggers three separate, independently-governed money questions. Conflating them is where sites get into trouble. This guide keeps them apart: (1) whether the visit can be billed as a claim to Medicare or another payer, (2) whether the site can charge the participant a practice-style no-show fee, and (3) whether the sponsor owes the site anything under the clinical trial agreement (CTA) regardless of what happened with the subject.
This is a narrow, practical companion to CASRAI’s broader Clinical Trial Billing Compliance checklist — read that first if you need the general coverage-analysis and claims-routing background. This page assumes that grounding and goes deep on the one scenario it doesn’t cover in depth: the visit that didn’t happen at all.
The three money flows around a missed visit
| Question | Who is being charged | Governing framework |
|---|---|---|
| Can the missed visit be billed as a claim? | Medicare / commercial payer | CMS coverage rules (NCD 310.1), claims-processing requirements, False Claims Act |
| Can the site charge a no-show fee? | The trial participant, directly | General Medicare no-show guidance, informed consent document (ICF), IRB review |
| Does the sponsor owe the site anything? | The sponsor, via the site | The clinical trial agreement (CTA) budget; Fair Market Value under Stark/Anti-Kickback |
1. Can you bill Medicare or insurance a claim for a missed visit?
No. This is the least ambiguous of the three questions. Medicare’s routine-cost coverage for a qualifying clinical trial under NCD 310.1 pays for items and services that are actually furnished to the beneficiary in connection with the trial — it is not a capitated or per-enrollment payment. If a subject doesn’t show up, no covered service was rendered, so there is no CPT/HCPCS-eligible encounter to code and no claim to submit. Billing a claim for a visit that didn’t occur — whether to Medicare, Medicaid, or a commercial payer — is billing for a service not rendered, which is a textbook False Claims Act exposure, not a gray area.
The same logic applies to the claims-processing mechanics sites already use for trial billing: the Advance Beneficiary Notice (ABN) process and Condition Code 30 institutional-claim marking exist to correctly route claims for services that were furnished within a qualifying trial. Neither has any application to a visit that never took place — there’s no claim to route in the first place. If a missed-visit charge is discovered on a submitted claim (for example, a bundled per-visit charge that got billed on autopilot by a scheduling-linked charge master without checking whether the subject actually presented), that is a billing error requiring the same overpayment analysis and, if material, the same OIG Self-Disclosure Protocol pathway CASRAI covers separately for coverage-analysis and billing-designation errors generally.
2. Can the site charge the participant a no-show fee directly?
This is where the three-lane distinction matters most, because the general rule for ordinary clinical practice does not transfer cleanly into a trial context.
Outside of research, CMS guidance and OIG’s longstanding position is that a practice may charge a Medicare beneficiary a missed-appointment fee, provided the charge functions as a business-office policy rather than a substitute bill for the missed service: it is set out in a written policy, applied uniformly to all patients regardless of payer source (not just Medicare beneficiaries), never billed to Medicare itself, and priced to reflect the missed scheduling opportunity rather than the value of the care that would have been delivered.
Inside a trial, that permissibility exists on paper but is rarely exercised in practice, for reasons specific to human-subjects research rather than to billing law as such:
- Informed consent scope. Most protocol informed consent documents (ICFs) include a costs section stating what the participant will and won’t be responsible for. A no-show fee that isn’t disclosed there is a cost the participant didn’t consent to, which is an IRB-reviewable consent-adequacy problem independent of whether the fee itself would otherwise be permissible under Medicare’s general no-show guidance.
- Coercion and undue-influence review. IRBs reviewing a study’s payment and cost provisions (per the Common Rule’s informed-consent requirements at 45 CFR 46) look at whether financial terms could pressure a subject’s decisions about continuing participation. A monetary penalty for a missed visit sits close enough to that line that most IRBs and sponsors avoid it rather than litigate the point.
- Payer-uniformity friction. The general Medicare no-show rule requires the policy apply identically regardless of payer. Trial participants are frequently a mix of Medicare beneficiaries, commercially insured subjects, and self-pay volunteers receiving the investigational product for free — designing a single uniformly-applied no-show fee across that population, on top of a protocol budget that already separately compensates the site for scheduling risk (see Section 3), adds administrative complexity most sites conclude isn’t worth the marginal recovery.
Net effect: charging trial participants directly for a missed visit is not categorically prohibited, but it requires IRB review and ICF disclosure before a site adopts it, and in practice most sites and sponsors instead route the entire cost of a missed visit through the sponsor relationship described below rather than passing any part of it to the participant.
3. Who pays the site: sponsor cost responsibility under the CTA
This is the lane that actually absorbs most of the real cost of a no-show, and it has nothing to do with CMS or the participant — it’s a contract term negotiated between sponsor and site in the clinical trial agreement (CTA) budget.
Two common budget structures handle this differently:
- Milestone/visit-based budgets pay the site a fixed amount when a subject reaches a defined visit or milestone. Under a strict version of this structure, a missed visit that is never made up may simply not trigger payment — the site absorbs the coordinator time, prepped supplies, and scheduled clinic capacity as a cost of doing the trial.
- Procedure- or activity-based budgets itemize payment by specific task (consent, blood draw, imaging, drug dispensing, coordinator time). Sites negotiating these budgets commonly push for a partial “visit fee” or “scheduling fee” line item that is payable whenever a visit is scheduled and staffed for, regardless of whether the subject actually presents — compensating the site’s sunk cost rather than the missed procedures themselves.
Neither structure is dictated by regulation; both are negotiated. What is regulated is the size and structure of the payment itself: sponsor payments to investigator sites, including any no-show or scheduling-fee component, must reflect Fair Market Value (FMV) for the work actually performed or the cost actually incurred, and must not be structured in a way that could be construed as compensation for referrals or enrollment volume. This is the same FMV discipline CASRAI covers in the context of investigator compensation generally — see Stark Law and Clinical Research: How the Physician Self-Referral Exception Applies to Investigators. A missed-visit fee priced to compensate documented site costs (coordinator hours already scheduled, non-refundable supply prep) is defensible; one that functions as a flat bonus untethered to actual site burden is a weaker position under both FMV and Anti-Kickback Statute analysis.
Practically, this means the budget negotiation — not the participant’s insurance card — is where a site should be resolving most of its no-show cost exposure. A well-negotiated CTA with a realistic no-show/scheduling-fee provision removes most of the pressure that might otherwise push a site toward billing a claim it shouldn’t (Section 1) or charging the participant directly (Section 2).
Where sites actually get this wrong
In practice, missed-visit billing problems trace back to one of a small number of patterns:
- Charge-master autopilot. A per-visit charge tied to a scheduling event fires automatically regardless of whether the subject presented, and nobody reconciles the claim against the actual encounter before it goes out. This is a claims-integrity failure, not a policy decision — and it’s exactly the kind of systemic billing error the OIG Self-Disclosure Protocol guide addresses once discovered.
- Treating the sponsor no-show payment as if it were a claim. A payment the sponsor makes to the site for a missed visit under the CTA is a contract payment for services/capacity, not a healthcare claim, and should never appear in the trial’s claims data or be confused with what was billed to Medicare or the participant — these are entirely separate ledgers.
- No written no-show policy at all. Sites that haven’t decided, in writing and with IRB sign-off, whether they charge participants directly tend to make inconsistent ad hoc calls per subject — which is itself the fact pattern general Medicare no-show guidance says disqualifies a fee from being permissible (it requires a uniform, disclosed, pre-existing policy, not a case-by-case decision).
A practical no-show billing policy checklist
- Confirm the informed consent document’s costs section addresses missed visits explicitly, one way or the other — silence is not the same as permission.
- If the site intends to charge participants a no-show fee, route that decision through the IRB as a consent-form and payment-provision matter before applying it, not after.
- Never let a scheduling event alone trigger a claim submission — require confirmation the encounter actually occurred before the claim goes to the payer.
- Negotiate the CTA budget’s no-show/scheduling-fee provision explicitly rather than leaving it implicit; specify whether it’s milestone-based (no pay if missed) or cost-recovery-based (partial pay for sunk site cost).
- Keep sponsor no-show payments and participant/payer billing on clearly separate accounting lines so an audit doesn’t have to untangle them after the fact.
- If a missed-visit charge is found on a submitted Medicare or Medicaid claim, treat it as a billing error requiring overpayment quantification and disclosure analysis, not a one-off correction.
Frequently asked questions
Can a site bill Medicare for a “no-show” administrative fee?
No. Medicare does not recognize or reimburse an administrative no-show fee as a covered service, for trial visits or otherwise. Any no-show fee a site charges must be billed directly to the individual, never submitted as a claim.
Does the sponsor’s no-show payment to the site count as a beneficiary inducement?
No — the federal beneficiary-inducement rules govern remuneration offered to a beneficiary to influence their choice of provider or service; a sponsor’s contractual payment to a site for scheduled-but-missed visit capacity runs between sponsor and site, not to the participant, so it isn’t analyzed under that framework. It is still subject to Fair Market Value and Anti-Kickback Statute scrutiny as investigator compensation.
If the informed consent form says participants won’t be charged for study visits, can the site still charge a no-show fee?
Not without going back through the IRB. A no-show fee is a cost to the participant that the existing consent language likely doesn’t cover, and charging it anyway risks being treated as a consent violation independent of whether the fee itself would be permissible under general Medicare no-show guidance.
What should happen to the sponsor-funded visit fee if the subject later completes a make-up visit?
This is a CTA drafting question, not a regulatory one — sponsors and sites should specify up front whether a make-up visit triggers its own full payment, a reduced payment netting out the earlier no-show fee, or no additional payment, so it isn’t negotiated ad hoc after the fact.
